Decoding the Immune Response in Early-Stage Bladder Cancer with Joshua Meeks, MD, PhD

Why does a standard immunotherapy work remarkably well for some bladder cancer patients, but fail for others? In this episode, Northwestern Medicine physician-scientist Joshua Meeks, MD, PhD, breaks down his recent research published in the Journal of Clinical Investigation and European Urology uncovering how the tumor microenvironment and immune cellular communication influence response to Bacillus Calmette-Guérin (BCG) immunotherapy. Find out how single-cell RNA sequencing, macrophage–T-cell interactions, and urinary tumor DNA biomarkers are paving the way for targeted, personalized bladder cancer care.